Regeneron Pharmaceuticals (REGN) Non-Current Assets (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Non-Current Assets of $23.3 billion for Q2 2026, up 9.01% year-over-year from $21.4 billion in Q2 2025, and up 2.76% quarter-over-quarter from $22.7 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Non-Current Assets (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $23.3 billion for Q2 2026.
- In Q2 2026, Non-Current Assets rose 9.01% year-over-year to $23.3 billion; the TTM figure through Jun 2026 stood at $90.7 billion (up 15.44% YoY), while the FY2025 annual figure was $22.5 billion, up 18.0% from the prior year.
- Non-Current Assets for Q2 2026 stood at $23.3 billion, up from $22.7 billion in the prior quarter.
- The five-year high for Non-Current Assets was $23.3 billion in Q2 2026, with the low at $11.7 billion in Q2 2022.
- The 5-year median for Non-Current Assets is $16.3 billion (2024), against an average of $16.9 billion.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 56.05% in 2022, then advanced 2.03% in 2023.
- Regeneron Pharmaceuticals' Non-Current Assets stood at $13.3 billion in 2022, then rose by 2.03% to $13.6 billion in 2023, then surged by 40.42% to $19.1 billion in 2024, then gained by 18.0% to $22.5 billion in 2025, then gained by 3.32% to $23.3 billion in 2026.
- Business Quant data shows REGN's Non-Current Assets at $23.3 billion in Q2 2026, $22.7 billion in Q1 2026, and $22.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 564.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.28 Bn |
| Mar 31, 2026 | 22.66 Bn |
| Dec 31, 2025 | 22.54 Bn |
| Sep 30, 2025 | 22.19 Bn |
| Jun 30, 2025 | 21.36 Bn |
| Mar 31, 2025 | 19.97 Bn |
| Dec 31, 2024 | 19.10 Bn |
| Sep 30, 2024 | 18.11 Bn |
| Jun 30, 2024 | 17.01 Bn |
| Mar 31, 2024 | 15.50 Bn |
| Dec 31, 2023 | 13.60 Bn |
| Sep 30, 2023 | 13.53 Bn |
| Jun 30, 2023 | 13.73 Bn |
| Mar 31, 2023 | 13.15 Bn |
| Dec 31, 2022 | 13.33 Bn |
| Sep 30, 2022 | 12.25 Bn |
| Jun 30, 2022 | 11.68 Bn |
| Mar 31, 2022 | 12.04 Bn |
| Dec 31, 2021 | 11.42 Bn |
| Sep 30, 2021 | 9.90 Bn |